ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression
Real-world data presented at ADA 2026 showcased the impact of Sanofi's teplizumab in slowing type 1 diabetes (T1D) progression.
Read the full article on the original site.
Read Full Article